Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Non-Current Assets (2017 - 2025)

Historic Non-Current Assets for Inmune Bio (INMB) over the last 9 years, with Q3 2025 value amounting to $2.7 million.

  • Inmune Bio's Non-Current Assets fell 8412.38% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.1 million, marking a year-over-year decrease of 4396.6%. This contributed to the annual value of $16.9 million for FY2024, which is 93.21% down from last year.
  • As of Q3 2025, Inmune Bio's Non-Current Assets stood at $2.7 million, which was down 8412.38% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Inmune Bio's Non-Current Assets peaked at $17.3 million during Q4 2021, and registered a low of $1.6 million during Q2 2025.
  • Over the past 5 years, Inmune Bio's median Non-Current Assets value was $17.0 million (recorded in 2024), while the average stood at $15.4 million.
  • In the last 5 years, Inmune Bio's Non-Current Assets skyrocketed by 401.32% in 2021 and then tumbled by 9027.01% in 2025.
  • Quarter analysis of 5 years shows Inmune Bio's Non-Current Assets stood at $17.3 million in 2021, then decreased by 1.26% to $17.1 million in 2022, then decreased by 0.36% to $17.1 million in 2023, then fell by 0.93% to $16.9 million in 2024, then crashed by 84.09% to $2.7 million in 2025.
  • Its Non-Current Assets stands at $2.7 million for Q3 2025, versus $1.6 million for Q2 2025 and $16.8 million for Q1 2025.